Skip to main content
Amy McKee, MD, Pediatric Hematology & Oncology, Cambridge, MA

AmyElizabethMcKeeMD

Pediatric Hematology & Oncology Cambridge, MA

Chief Medical Officer PAREXEL International

Dr. McKee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. McKee's full profile

Already have an account?

  • Office

    245 Main Street
    Cambridge, MA 02142
    Phone+1 202-655-8185

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2003 - 2006
  • Tufts Medical Center
    Tufts Medical CenterResidency, Pediatrics, 2000 - 2003
  • Tulane University School of Medicine
    Tulane University School of MedicineClass of 2000

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2003 - 2025

Awards, Honors, & Recognition

  • National Cancer Institute Director’s Innovation Award/Career Development Award National Cancer Institute, NIH, 2008

Publications & Presentations

PubMed

Journal Articles

  • FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.  
    Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, Sridhara R, Lee E, Tzou A, Philip R, Chiu HJ, Ricks TK, Palmby T, Russell AM, Ladouceur G, Pfuma E, Li H, Zhao L, Li..., Clin Cancer Res, 2015
  • NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.  
    Venook AP, Arcila ME, Benson AB 3rd, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, R..., J Natl Compr Canc Netw, 2014
  • PKC-mediated survival signaling in breast carcinoma cells: a role for MEK1-AP1 signaling.  
    Weldon CB, McKee A, Collins-Burow BM, Melnik LI, Scandurro AB, McLachlan JA, Burow ME, Beckman BS., Int J Oncol, 2005
  • Join now to see all

Abstracts/Posters

  • Unlike Other Cancers, Neuroblastoma Contains a High Frequency of Tumor-initiating Cells with Stem Cell-Like Behavior.
    Amy E. McKee, Loen M. Hansford, David Venzon, David R. Kaplan, Carol J. Thiele., Advances in Neuroblastoma Research Meeting, 2008
  • BDNF/TrkB pathway upregulates PTHrP in neuroblastoma.
    Amy E. McKee, Kelly Martin, Ana Markovic, Braden T. Greer, Jun S. Wei, Qing R. Chen, Javed Khan, and Carol J. Thiele., American Association of Cancer Research Annual Meeting, 2006
  • PTHrP, a Mediator of Bone Metastasis, Is a Target of TrkB but Not TrkA in Neuroblastoma.
    Amy E McKee, Kelly Martin, Katsuya Nakamura, Braden Greer, Jun Wei, Javed Khan, Carol J Thiele., Advances in Neuroblastoma Research, 2006
  • Join now to see all

Lectures

  • Regulatory Science: The Challenges with "SMALL DATA": Small Trials, Off-Label Use, and Single Patient INDs—Are We Doing Enough? 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

  • Parexel Introduces Expert Series - New Medicines, Novel Insights
    Parexel Introduces Expert Series - New Medicines, Novel InsightsFebruary 28th, 2023
  • Medicenna Therapeutics to Present at Upcoming March Investor Conferences
    Medicenna Therapeutics to Present at Upcoming March Investor ConferencesDecember 9th, 2020
  • Parexel Hiring Spree Continues as It Nabs China, U.S. And Europe Regulator Alumni
    Parexel Hiring Spree Continues as It Nabs China, U.S. And Europe Regulator AlumniJuly 27th, 2020
  • Join now to see all